Category: 103946-54-9

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103946-54-9,4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid,as a common compound, the synthetic route is as follows.

bpyAc (34.9 mg, 0.163 mmol) and fac-[Re(CO)3(dmso-O)3](PF6)(102.8 mg, 0.157 mmol) were dissolved in dry acetone (10 mL).The mixture was stirred at reflux for 4 h under argon. The solutionwas concentrated at ca. 2 mL and the precipitation of the productwas induced by slow diffusion of diethyl ether. A pure yellowpowder was isolated by filtration and washed with ether. Yield83 mg, 0.117 mmol (75%). Anal. Calc. for C17H16F6N2O6PReS(Mw = 707.56): C, 28.86; H, 2.28; N, 3.96; S, 4.53. Found: C,28.97; H, 2.35; N, 3.78; S, 4.62%. 1H NMR (d, 500 MHz, CD3NO2):9.31 (d, 3J60,50 = 5.6 Hz, 1H, H60), 8.99 (d, 3J6,5 = 5.6 Hz, 1H, H6), 8.92(s, 1H, H30), 8.52 (s, 1H, H3), 8.21 (d, 3J50,60 = 5.6 Hz, 1H, H50), 7.66(d, 3J5,6 = 5.5 Hz, 1H, H5), 2.67 (s, 3H, -CH3), 2.63 (s, 3H, -CH3(dmso)),2.61 (s, 3H, -CH3(dmso)). 1H NMR (d, 500 MHz, dmso-d6): 9.25 (d,3J60,50 = 5.5 Hz, 1H, H60), 9.04 (s, 1H, H30), 8.96 (d, 3J6,5 = 5.6 Hz, 1H,H6), 8.94 (s, 1H, H3), 8.14 (d, 3J50,60 = 5.7 Hz, 1H, H50), 7.69 (d,3J5,6 = 5.2 Hz, 1H, H5), 4.02 (s, 1H, -OH), 2.59 (s, 3H, -CH3). 13CNMR (d, 126 MHz, CD3NO2): 196.50 (s, COfac), 196.35 (s, COfac),191.30 (s, COfac), 164.35 (s, -COOH), 157.39 (s, C20), 154.89 (s,C40), 154.59 (s, C2), 154.25 (s, C60), 152.68 (s, C6), 142.04 (s, C4),128.94 (s, C5), 126.74 (s, C50), 125.19 (s, C3), 123.03 (s, C30), 37.64(d, 2C, -CH3(dmso)), 20.41 (s, -CH3). Selected IR bands (cm1, KBrpellets): 2029 (mCOfac), 1916 (mCOfac), 1710 (mCOacid), 947 (mSO),842 (mP-F), 558 (mP-F). UV-Vis (kmax, nm, CH2Cl2): 295, 318sh,331sh, 375., 103946-54-9

As the paragraph descriping shows that 103946-54-9 is playing an increasingly important role.

Reference£º
Article; Cavigli, Paolo; Balducci, Gabriele; Zangrando, Ennio; Demitri, Nicola; Amati, Agnese; Indelli, Maria Teresa; Iengo, Elisabetta; Inorganica Chimica Acta; vol. 439; (2016); p. 61 – 68;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

103946-54-9, 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

103946-54-9, 4,4′-Dimethyl-2,2′-bipyridine (1.5 g, 8 mmol) and selenium dioxide (887.68 mg, 8 mmol) were refluxed in 100 ml of 1,4-dioxane for 24 hours, after cooling to room temperature, the black solid was filtered off and solvent was removed by evaporation to give a white solid. This solid was dissolved by stirring with 100 ml of ethyl acetate, the insoluble material was filtered off, and the filtrate was washed three times with 20 ml of a 1.0 M sodium carbonate solution. The organic phase was extracted three times with 50 ml of 0.3 M sodium metabisulfite solution, the aqueous phase was combined, the pH was adjusted to 10 with sodium carbonate solution, and extracted four times with 20 ml of chloroform, the organic phase was combined, which was dried over anhydrous sodium sulfate and solvent was removed by evaporation to give a crude product. The crude product was purified by column chromatography eluting with petroleum ether / ethyl acetate (1: 4) to give aldehyde-substituted bipyridine 398 mg was obtained in a yield of 25%. The aldehyde-substituted bipyridine was dissolved in 20 ml of ethanol, stirred with 4 ml of a silver nitrate aqueous solution, then 10 ml of a 1.0 M aqueous sodium hydroxide solution was slowly added and reacted at room temperature for 15 hours. The solvent was removed by evaporation and the solid was washed twice with 4 ml of 1.3 M sodium hydroxide and 4 ml of water, the combined filtrate was extracted three times with 10 ml of chloroform, aqueous phase pH was 3.5 with 4 M hydrochloric acid, the resulting white solid was filtered and dried in vacuo to give carboxy-substituted bipyridine 258 mg, yield 60%. The resulting carboxyl substituted bipyridine (1.3 mmol) was all dissolved in 20 ml DMF, then aminothiazole compound (300 mg, 1.3 mmol), 1-hydroxy-7-azobenzotriazole (1.3 mmol, 177 mg), 4-dimethylaminopyridine (1.3 mmol, 146 mg), 1-ethyl-carbonyldiimide hydrochloride (1.3 mmol, 87 mg) were added thereto, and stirred at room temperature for 6 hours. The obtained solid was filtered, washed four times with 25 ml of water and dried in vacuo to give the Aminothiazole functional group-substituted polypyridine ligand (L1) 457 mg, yield 82%. All the obtained L1 (1.06 mmol) and the compound cis-[Ru(bpy)2Cl2].2H2O (442 mg, 0.85 mmol) were refluxed under 20 ml of ethylene glycol and argon gas protection for 8 hours. After cooling to room temperature, 10 ml of a saturated aqueous solution of ammonium hexafluorophosphate was added,the obtained orange precipitate was filtered, washed once with 15 ml of water, washed three times with 30 ml of anhydrous diethyl ether and dried in vacuo to give crude product. The crude product is subjected to neutral alumina column chromatography, and the only orange component is eluted with acetonitrile to obtain the target polypyridyl ruthenium complex Ru1, amount 616 mg, yield 64%

103946-54-9 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid 11127621, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Yunnan University; Gao Feng; Yan Ru; Bi Xudan; (15 pag.)CN109232663; (2019); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103946-54-9,4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid,as a common compound, the synthetic route is as follows.

[(Cp*)Ir(mu-Cl)Cl]2 (39.8 mg, 0.05 mmol) was dissolved in methanol(20 mL) followed by addition of the 4-methyl-4?-carboxy-2,2?-bipyridine ligand (21.4 mg, 0.10 mmol). The mixture was stirred at313 K overnight. The final yellow solution was filtered, concentratedand NH4PF6 (163 mg, 1.0 mmol) was added to the solution. This solutionwas kept at 277 K overnight. The yellow precipitate was collectedby filtration and dried under vacuum. Yield 66 mg, 91%; 1H NMR(400 MHz, d4-MeOD, 298 K): delta 9.11 (d, 1H, J = 5.8 Hz), 9.00 (s, 1H),8.81 (d, 1H, J=5.8 Hz), 8.61 (s, 1H), 8.26 (d, 1H, J=5.8 Hz), 7.71 (d,1H, J = 6.1 Hz), 2.70 (s, 3H), 1.72 (s, 15H); 13C NMR (125 MHz, d4-MeOD, 298 K): 165.79, 158.15, 155.99, 155.08, 154.10, 152.47,143.72, 131.21, 129.19, 126.65, 124.58, 91.28, 21.39, 8.67; high resolutionESI-MS m/z calcd for [(M-PF6-H)+Na]+ 599.1040, found599.1038.

103946-54-9, As the paragraph descriping shows that 103946-54-9 is playing an increasingly important role.

Reference£º
Article; Zhang, Wen-Ying; Banerjee, Samya; Imberti, Cinzia; Clarkson, Guy J.; Wang, Qian; Zhong, Qian; Young, Lawrence S.; Romero-Canelon, Isolda; Zeng, Musheng; Habtemariam, Abraha; Sadler, Peter J.; Inorganica Chimica Acta; vol. 503; (2020);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

103946-54-9, 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Bis-2,2′-bipyridine ruthenium dichloride (55 mg, 0.11 mmol) Methyl-2,2′-bipyridine-4-carboxylic acid (21 mg, 0.11 mmol) were protected from light in the presence of ethanol (10 mL, 50%) under argon for 5 hours. The reaction mixture was evaporated and the residue was dissolved in 1 mL CH3CN, Add 2 mL of saturated n-butylamine in acetone. The resulting precipitate was filtered, Washed with acetone, And vacuum dried, This gave 79 mg (85%) of Ru-CO2H as a red-orange powder. (Synthesis route shown in Figure 4)., 103946-54-9

103946-54-9 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid 11127621, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Capital Medical University; Li, Minna; Peng, Shiqi; Zhao, Ming; (10 pag.)CN106146565; (2016); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103946-54-9,4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid,as a common compound, the synthetic route is as follows.

As shown in Figure 1, 4′-methyl-[2,2’dipyridyl]-4-carboxylic acid (0.3 g, 1.4 mmol) (purchased from Zhengzhou Alpha) and N-hydroxysuccinimide (NHS, 0.257 g, 2.24 mmol) were used and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 0.322 g, 1.68 mmol) was dispersed in a 15 mL DMF (N,N-dimethylformamide) port flask , Heat to 50 C, reaction for 12h. After the reaction was completed, the DMF solution was decontaminated under reduced pressure. Deionized water (50 mL) was added and solids precipitated.Dichloromethane extraction (15 mL, extraction 3 times) takes a light yellow organic layer. Then dry with anhydrous sodium sulfate.Take the filtrate, take the filtrate, and evaporate the filtrate with a rotary evaporator.A pale white solid is obtained, which is the active ester of dipyridylcarboxyl: 2,5-dicarbonyl-1-pyrrolidinyl 4′-methyl-[2,2′-bipyridine]-4-carboxylate (product 1), yield 65.2%., 103946-54-9

103946-54-9 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid 11127621, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Jinan University; Guangzhou Medicine Jianyansuo; Chen Tianfeng; Tian Yiqiao; Du Biying; Huang Yanyu; Gao Pan; (22 pag.)CN107573384; (2018); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103946-54-9,4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid,as a common compound, the synthetic route is as follows.

103946-54-9, Weigh the NH2-C4 dichloro bridge 1mmolAnd 2.2 mmol of 4-methyl 4′-carboxy-2,2′-bipyridine was added to the reaction flask, vacuumed, and protected with nitrogen.Reacted at 40 C for 10 h,After adding KPF630mmol reaction for 2h,Spin dry, extract with dichloromethane (3 ¡Á 150mL), take the organic phase, spin dry into silica gel powder column, separate and purify,The yield was 59%.

103946-54-9 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid 11127621, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Nanjing University of Posts and Telecommunications; Zhang Yin; Wei Huanjie; Zhang Taiwei; Zhao Qiang; Liu Shujuan; Huang Wei; (11 pag.)CN107880076; (2018); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

103946-54-9, 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

87 mg of 4′-methyl- (2,2′-bipyridine) -4-carboxylic acid was dissolved in anhydrous THF and dissolved in anhydrous DMF. Under ice bath conditions, HOBt 55mg and DCC 100mg were completely dissolved and activated for 30min.The prepared HCl ¡¤ Arg (Tos) -Gly-Asp (OBzl) -Ser-OBzl 312 mg was added and the pH adjusted to 8.0-9.0 with DMM. The reaction was stirred at room temperature for 14h,The reaction was monitored by TLC plate. 328 mg (89% of product) of a pink solid powder was obtained., 103946-54-9

The synthetic route of 103946-54-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Capital University of Medical Sciences; Cui Chunying; Lin Na; (23 pag.)CN107320736; (2017); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103946-54-9,4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid,as a common compound, the synthetic route is as follows.

Under anhydrous anaerobic conditions, 214 mg (1 mmol) of 4′-methyl-2,2′-bipyridinyl-4-carboxylic acid was added to 50 mL of bisChlorinated sulfoxide solvent, heated to 80 C reflux, stirring 3h after the reaction, the solvent spin to remove, the remaining solid dissolved in 50mL of anhydrous methylene chloride, 0 in the case of ice drop 244 mg (hydrazinocarbonyl) ferrocene and 130 muL of triethylamine in anhydrous dichloromethane was added dropwise. After completion of the dropwise addition, the reaction was stopped after stirring for 3 h in an ice bath. The reaction was quenched to room temperature, the solvent was removed by spin- (V: V = 40: 1), and the solvent was dried to give 4′-methyl-2,2′-bipyridyl-4- (hydrazinocarbonyl) bis Ferrocene, 103946-54-9

The synthetic route of 103946-54-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Shaanxi Normal University; Zhang Chengxiao; Han Danjuan; Qi Honglan; (14 pag.)CN106892947; (2017); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI